Home / Press Release / FDA approves new drug Cinqair to be used against Asthma

FDA approves new drug Cinqair to be used against Asthma

The United States Food and Drug Administration on Wednesday approved Teva Pharmaceutical’s drug Cinqair that could treat severe asthma for good. The drug has been marked for the individuals whp suffer from severe asthma attacks in spite of being on medication. The drug that has been recently approved by the United States Food and Drug Administration is named Cinqair and is going to be in the market with three other drugs that potentially provide similar sort of remedies.

Teva Pharmaceutical’s Cinqair will be competing with the likes of Nucala by GlaxoSmithKline and Xolair developed by Novartis and Roche Holding. Nucala was approved by the FDA in just a few months ago. Like Cinqair, Nucala is also an antibody that actually helps in reducing the levels of eosinophils in the blood of an asthma patient. Eosinophils is a type of white blood cell that to a certain extend adds on to the development of Asthma.

Asthma is one of those diseases that have plagued United States for quite some time now. As it happens, approximately 22 million citizens of the United States of America suffered from the disease in the year 2013. According to the reports, the United States Center for Disease Control and Prevention notes down about 400,000 plus asthma related patients being hospitalized every year. Not to mention the many cases that does not even come into the frame.

Reports also suggests that before the drug by Teva Pharmaceuticals was approved, the FDA went through a lot of study regard to what kind of impact the drug could possibly have on an asthma patient. In a study, it was shown that individuals who were given Cinqair after the first asthma attack, suffered comparatively less number of attacks that the other patients. It will be interesting to see how the drug by Teva Pharmaceuticals, Cinqair is priced.

Contact Information
24/7 Research Support
Phone: +1-855-455-8662
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on Rss
Add us on Google +